As at Jul 25, 2024, the ABBV stock has a PE ratio of 54.06. This is based on the current EPS of $3.37 and the stock price of $182.17 per share. An increase of 21% has been seen in the P/E ratio compared to the average of 44.8 of the last 4 quarters.
The mean historical PE ratio of AbbVie over the last ten years is 28.0. The current 54.06 PE ratio is 93% above the historical average. Over the past ten years, ABBV's PE ratio was at its highest in the Dec 2014 quarter at 58.95, with a price of $65.44 and an EPS of $1.11. The Mar 2020 quarter recorded the bottom point at 13.44, with a price of $76.19 and an EPS of $5.67.
Maximum annual increase: 187.98% in 2014
Maximum annual decrease: -68.09% in 2015
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 56.77 | 133.62% |
| 2022 | 24.3 | 16.27% |
| 2021 | 20.9 | -46.75% |
| 2020 | 39.25 | 134.89% |
| 2019 | 16.71 | -33.48% |
| 2018 | 25.12 | -14.03% |
| 2017 | 29.22 | 70.28% |
| 2016 | 17.16 | -8.77% |
| 2015 | 18.81 | -68.09% |
| 2014 | 58.95 | 187.98% |
ABBV's current P/E ratio is above the 3, 5 and 10-year historical averages.
ABBV's PE ratio is lower than its peer stocks LLY and GILD, but it is greater than AZN's and AMGN's. AbbVie's current PE ratio of 54.06 is above the average of its peers, which is 38.2.
| Stock name | PE ratio | Market cap |
|---|---|---|
| BIIB Biogen Inc | 26.23 | $30.75B |
| AZN Astrazeneca plc | 37.56 | $242.2B |
| NBIX Neurocrine Biosciences Inc | 38.94 | $14.77B |
| AMGN Amgen Inc | 47.56 | $179.63B |
| ABBV AbbVie Inc | 54.94 | $326.97B |
| LLY ELI LILLY & Co | 117.98 | $764.72B |
| GILD Gilead Sciences Inc | 192.53 | $95.94B |
| PFE Pfizer Inc | N/A | $174.36B |
| BMY Bristol Myers Squibb Co | N/A | $102.27B |
As of Jul 25, 2024, ABBV stock has a price to earnings ratio of 54.06.
The average PE ratio for ABBV stock over the past 3 years is 31.85.
The average PE ratio for ABBV stock over the past 5 years is 29.57.
Over the last ten years, the quarterly PE ratio reached a historic high of 58.95 in the Dec 2014 quarter.
ABBV's current price to earnings ratio is 93% above its 10-year historical average.
The PE ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Jul 25, 2024), AbbVie's stock price is $182.17. The earnings per share for the trailing twelve months (TTM) ending Mar 2024 is $3.37. Therefore, AbbVie's P/E ratio for today is 54.06. PE RATIO(54.06) = STOCK PRICE($182.17) / TTM EPS($3.37)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.